104 related articles for article (PubMed ID: 38948068)
21. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
Norrby K
APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
[TBL] [Abstract][Full Text] [Related]
22. Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
André N; Tsai K; Carré M; Pasquier E
Trends Cancer; 2017 May; 3(5):319-325. PubMed ID: 28718409
[TBL] [Abstract][Full Text] [Related]
23. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
Hida K; Kikuchi H; Maishi N; Hida Y
Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
[TBL] [Abstract][Full Text] [Related]
24. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package.
Bahl A; Bakhshi S
Indian J Pediatr; 2012 Dec; 79(12):1617-22. PubMed ID: 22544675
[TBL] [Abstract][Full Text] [Related]
25. Metronomic chemotherapy and immunotherapy in cancer treatment.
Chen YL; Chang MC; Cheng WF
Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
[TBL] [Abstract][Full Text] [Related]
26. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
Munzone E; Colleoni M
Cancer Lett; 2017 Aug; 400():259-266. PubMed ID: 28093280
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
[TBL] [Abstract][Full Text] [Related]
28. Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.
Wichmann V; Eigeliene N; Saarenheimo J; Jekunen A
Acta Oncol; 2020 Jul; 59(7):775-785. PubMed ID: 32275176
[No Abstract] [Full Text] [Related]
29. Metronomic therapy: chemotherapy revisited.
Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
[TBL] [Abstract][Full Text] [Related]
30. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
31. Metronomics chemotherapy: time for computational decision support.
Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
[TBL] [Abstract][Full Text] [Related]
32. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
33. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
Kareva I; Waxman DJ; Lakka Klement G
Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
[TBL] [Abstract][Full Text] [Related]
34. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
35. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
36. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
37. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
38. Role of vascular normalization in benefit from metronomic chemotherapy.
Mpekris F; Baish JW; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
[TBL] [Abstract][Full Text] [Related]
39. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
40. METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.
Launay S; Sabatier R; Brunelle S; Esterni B; Tarpin C; Viret F; Gravis G; Cappiello M; Provansal M; Extra JM; Bertucci F; Viens P; Goncalves A
Anticancer Res; 2016 Jan; 36(1):293-9. PubMed ID: 26722056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
